Fresh ADHD drug shortage prompts TGA warning to doctors
The TGA said in April that shortages might be over, but drug sponsor Takeda Pharmaceuticals has warned of new supply issues.
The TGA is urging doctors to “limit” prescribing of the ADHD medication Vyvanse to new patients until at least October amid rolling shortages.
The 20mg capsules of Vyvanse — a brand of lisdexamfetamine dimesilate — is currently in shortage, while the 60mg dose is expected to be in shortage from late August, the regulator said on Tuesday.
According to drug sponsor Takeda Pharmaceuticals, the supply issues were caused by an “unexpected increase in consumer demand”.
As a result, the TGA has urged patients to contact their prescriber to potentially switch to an alternative dosing regimen.
